Clinical trial · no report yet · Phase 3
PACIFIC2
Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer
- NCT03519971 ↗
- Completed
- AstraZeneca
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 120 | |
| Podcasts | 31 | |
| YouTube | 21 |
The trial
ClinicalTrials.gov- Official title
- A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Given Concurrently With Platinum-based Chemoradiation Therapy in Patients With Locally Advanced, Unresectable NSCLC (Stage III) (PACIFIC2)
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Durvalumab; Placebo; Cisplatin/ Etoposide; Carboplatin/ Paclitaxel; Pemetrexed/ Cisplatin; Pemetrexed/ Carboplatin; Radiation
- Arms
- Arm 1: Durvalumab + platinum-based chemotherapy and radiation · Experimental
- Arm 2: Placebo + platinum-based chemotherapy and radiation · Placebo comparator
- Enrollment
- 328
- Primary outcomes
- Progression-Free Survival (PFS)
- Sponsor
- AstraZeneca
- Start
- Mar 29, 2018
- Primary completion
- Sep 7, 2023
- Results posted
- Yes
- Registry record
- NCT03519971 · updated Jul 14, 2026